Affiliation
Department of Respiratory Medicine, Cork University Hospital, Wilton, Cork, Ireland.Issue Date
2011-11MeSH
Anti-Inflammatory AgentsAnticoagulants
Antioxidants
Clinical Trials as Topic
Combined Modality Therapy
Disease Progression
Humans
Idiopathic Pulmonary Fibrosis
Immunosuppressive Agents
Lung Transplantation
Medication Therapy Management
Outcome Assessment (Health Care)
Oxygen Inhalation Therapy
Palliative Care
Receptors, Endothelin
Tumor Necrosis Factor-alpha
Metadata
Show full item recordCitation
Idiopathic pulmonary fibrosis: treatment update. 2011, 28 (11):986-99 Adv TherJournal
Advances in therapyDOI
10.1007/s12325-011-0066-5PubMed ID
21975927Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.Language
enISSN
1865-8652Ethical Approval
N/Aae974a485f413a2113503eed53cd6c53
10.1007/s12325-011-0066-5